Buscador de ensayos clínicos de Fight CRC
| NCT ID | Title | Fase | Date Added | Ubicación | Prior IO Allowed | CRC-directed | Status | Drogas | Etiquetas |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Fase
Fase 1
|
Date Added 2019-12-04 |
Ubicación
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Bélgica Canadá Alemania Italia Japón Corea, República de Países Bajos España Taiwán Reino Unido |
Prior IO Allowed Sí |
CRC-directed No |
Status
Reclutamiento
|
Drogas
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06850103 |
TitleSCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases | Fase
Fase 2
|
Date Added 2025-03-25 |
Ubicación |
Prior IO Allowed No |
CRC-directed Sí |
Status
Aún no se ha contratado
|
Drogas |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT06835179 |
TitleSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | Fase
Fase 2
|
Date Added 2025-02-19 |
Ubicación |
Prior IO Allowed No |
CRC-directed Sí |
Status
Aún no se ha contratado
|
Drogas |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT06794086 |
TitleSBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases | Fase
Fase 3
|
Date Added 2025-01-27 |
Ubicación
China
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | Fase
Fase 1
|
Date Added 2017-10-18 |
Ubicación
Arizona, United States
California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japón Reino Unido |
Prior IO Allowed No |
CRC-directed No |
Status
Reclutamiento
|
Drogas
mRNA-4157, Pembrolizumab, Keytruda |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT02617277 |
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | Fase
Fase 1
|
Date Added 2015-11-30 |
Ubicación
Colorado, United States
Florida, United States Tennessee, United States |
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
AZD1775, MEDI4736 |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT05243862 |
TitleSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | Fase
Fase 2
|
Date Added 2022-02-17 |
Ubicación
Arizona, United States
Florida, United States Minnesota, United States |
Prior IO Allowed No |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Atezolizumab, PolyPEPI1018, Tecentriq |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT06065371 |
TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Fase
Fase 1
|
Date Added 2023-10-03 |
Ubicación
Michigan, United States
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
capecitabine, Sacituzumab govetican |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Fase
Fase 2
|
Date Added 2017-12-07 |
Ubicación
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico |
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
Etiquetas
MSS/ MMRp
|
| NCT ID NCT05733611 |
TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Fase
Fase 2
|
Date Added 2023-02-17 |
Ubicación |
Prior IO Allowed No |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas |
Etiquetas
MSS/ MMRp
|
